| 46.79 Delayed Data As of May 17 |  0.00 / 0.00%Today’s Change | 41.23 Today|||52-Week Range 52.83 | +1.56% Year-to-Date |
| Sofinnova Ventures Inc Buys Novo Nordisk A/S, Allergan PLC, Alnylam Pharmaceuticals I... May 15 / GuruFocus News - Paid Partner Content | Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug May 10 / Zacks.com - Paid Partner Content |
| Pioneer Investment Management Inc Buys Linde PLC, Progressive Corp, Royal Dutch Shell... May 13 / GuruFocus News - Paid Partner Content | Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug May 09 / MotleyFool.com - Paid Partner Content |
| Previous close | 46.79 |
| Today’s open | 46.80 |
| Day’s range | 46.75 - 47.11 |
| Volume | 1,027,966 |
| Average volume (3 months) | 1,351,009 |
| Market cap | $86.3B |
| Earnings growth (last year) | +8.07% |
| Earnings growth (this year) | +0.28% |
| Earnings growth (next 5 years) | +8.90% |
| Revenue growth (last year) | +4.51% |
| P/E ratio | 19.7 |
| Price/Sales | 6.31 |
| Price/Book | 14.40 |
| Today’s change | Today’s % change | |
|---|---|---|
| BMYBristol-Myers Squibb | -0.27 | -0.57% |
| AZNAstraZeneca | -0.02 | -0.05% |
| GSKGlaxoSmithKline | +0.12 | +0.31% |
| CELGCelgene | -0.09 | -0.09% |
| Next reporting date | August 9, 2019 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $17.7B |
| Annual profit (last year) | $6.1B |
| Net profit margin | 34.54% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President & Chief Executive Officer Lars Fruergaard Jørgensen |
Executive Vice President- International Operations Maziar Mike Doustdar |
Corporate headquarters Bagsværd, Capital Region |
